title: [Preoperative concomitant radiochemotherapy in bulky carcinoma of the cervix: Institut Curie experience].
abstract: OBJECTIVE
  To evaluate the treatment results of patients (pts) with Figo stage IB2, IIA, IIB cervical carcinoma (CC) treated with preoperative radiochemotherapy, followed by extended radical hysterectomy.
  
  
  METHODS
  Retrospective study of 148 women treated at the Institut Curie for operable Figo Stage IB2 to IIB, biopsy proved CC. Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radiocisplatinum based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy. Kaplan-Meier estimates were used to draw survival curves. Comparisons of survival distribution were assessed by the log-rank test.
  
  
  RESULTS
  Complete histological local-regional response was obtained in 56% of the pts (n=39). Residual macroscopic or microscopic disease in the cervix was observed in 28 pts (40%). All but one had in situ microscopic residual CC. Lateral residual disease in the parametria was also present in nine pts, all with residual CC. Pelvic lymph nodes were free from microscopic disease in 56 pts (80%). Eight of 55 (11%) radiological N0 patients had microscopic nodal involvement, as compared to 6/15 (40%) radiological N1 (p=0.03). Seventeen pts (25%) had residual cervix disease but negative nodes. After median follow-up of 40 months (range, 8-141), 38/70 patients (54.1%) are still alive and free of disease, six (8.6%) alive with disease, and 11 (15.8%) patients were lost for follow-up but free of disease.
  
  
  CONCLUSIONS
  The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.
authors.affiliation: Groupe de gynécologie, service d'oncologie et de radiothérapie, institut Curie, 26 rue d'Ulm, Paris cedex 05, France.
authors.forename: Y M
authors.initials: YM
authors.lastname: Kirova
authors.forename: Z
authors.initials: Z
authors.lastname: Bourhaleb
authors.forename: S
authors.initials: S
authors.lastname: Alran
authors.forename: M
authors.initials: M
authors.lastname: Campitelli
authors.forename: C
authors.initials: C
authors.lastname: Plancher
authors.forename: V
authors.initials: V
authors.lastname: Fourchotte
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: P
authors.initials: P
authors.lastname: Petrow
authors.forename: P
authors.initials: P
authors.lastname: Cottu
authors.forename: P
authors.initials: P
authors.lastname: de Cremoux
authors.forename: X
authors.initials: X
authors.lastname: Sastre-Garau
authors.forename: A
authors.initials: A
authors.lastname: de la Rochefordière
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods; D002173:Cancer Care Facilities; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D005602:France; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D055815:Young Adult